Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report Conference

Tsien, C, Pugh, S, Dicker, AP et al. (2019). Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 105(1), S78-S78. 10.1016/j.ijrobp.2019.06.539

Open Access

cited authors

  • Tsien, C; Pugh, S; Dicker, AP; Raizer, JJ; Matuszak, MM; Lallana, E; Huang, J; Algan, O; Taylor, N; Portelance, L; Villano, J; Hamm, J; Oh, KS; Ali, AN; Kim, MM; Lindhorst, S; Mehta, MP

sustainable development goals

authors

date/time interval

  • September 15, 2019 -

publication date

  • September 1, 2019

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Radiology, Nuclear Medicine & Medical Imaging
  • Science & Technology

Location

  • IL, Chicago

Digital Object Identifier (DOI)

Conference

  • 61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)

publisher

  • ELSEVIER SCIENCE INC

start page

  • S78

end page

  • S78

volume

  • 105

issue

  • 1